New salivary anti-haemostatics containing protective epitopes from Ornithodoros moubata ticks: Assessment of their individual and combined vaccine efficacy
| Autor: | Ana Oleaga, Verónica Díaz-Martín, Ricardo Pérez-Sánchez, Raúl Manzano-Román |
|---|---|
| Přispěvatelé: | Ministerio de Ciencia e Innovación (España) |
| Rok vydání: | 2015 |
| Předmět: |
Male
Models Molecular Protein Conformation Molecular Sequence Data Immunization Secondary Tick Recombinant antigens Hemostatics Epitope Ornithodoros moubata Animals Amino Acid Sequence Antigens Cloning Molecular Ornithodoros Saliva Vaccines General Veterinary biology Vaccine trial Proteins General Medicine biology.organism_classification Vaccine efficacy Virology Recombinant Proteins Vaccination Salivary antigens B-cell epitopes Epitopes B-Lymphocyte Platelet aggregation inhibitor Female Parasitology Rabbits Vaccine |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname |
| ISSN: | 0304-4017 |
| DOI: | 10.1016/j.vetpar.2015.08.005 |
| Popis: | 45 páginas, 6 figuras, 5 tablas. -- The definitive version is available at http://wwww.elsevier.com Ornithodoros moubata is the main vector of the pathogens causing African swine fever and human relapsing fever in Africa. The development of an efficient vaccine against this tick would facilitate its control and the prevention of the diseases it transmits to a considerable extent. Previous efforts to identify vaccine target candidates led us to the discovery of novel salivary proteins that probably act as anti-haemostatics at the host-tick interface, including a secreted phospholipase A2 (PLA2), a 7DB-like protein (7DB-like), a riboprotein 60S L10 (RP-60S), an apyrase (APY), and a new platelet aggregation inhibitor peptide, designated mougrin (MOU). In this work, the corresponding recombinant proteins were expressed in Escherichia coli and their individual vaccine efficacy was tested in rabbit vaccination trials. All of them, except the less immunogenic RP-60S, induced strong humoral responses that reduced tick feeding and survival, providing vaccine efficacies of 44.2%, 43.2% and 27.2%, 19.9% and 17.3% for PLA2, APY, MOU, RP-60S and 7DB-like, respectively. In the case of the more protective recombinant antigens (PLA2, APY and MOU), the immunodominant protective linear B-cell epitopes were identified and their combined vaccine efficacy was tested in a second vaccine trial using different adjuvants. In comparison with the best efficacy of individual antigens, the multicomponent vaccine increased vaccine efficacy by 13.6%, indicating additive protective effects rather than a synergistic effect. Tick saliva inoculated during natural tick-host contacts had a boosting effect on vaccinated animals, increasing specific antibody levels and protection Spanish Ministry of Science and Innovation (Grant no. GL2010-18164). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect